Loading organizations...
§ Private Profile · Northampton, Northamptonshire, United Kingdom
Diagnostics company developing rapid Antimicrobial Susceptibility Testing (AST) technology for clinical laboratories, identifying effective.
iFast Diagnostics, based in Whiteley, Hampshire, United Kingdom, develops rapid Antimicrobial Susceptibility Testing (AST) technology identifying effective antibiotics against bacterial infections in under three hours. Its platform uses electrical impedance on a microfluidic chip to measure bacteria, enabling faster antibiotic selection and reducing unnecessary antibiotic use. The company has secured approximately £5 million ($6.5 million) in seed funding from lead investors Raw Ventures, QantX, UKI2S, KHP Ventures, and Kadmos Capital, alongside a £1 million NIHR grant. CEO Toby King oversees commercialization, building on 12 years of research by Prof Hywel Morgan and Dr Daniel Spencer, originating from the University of Southampton. iFast Diagnostics was founded in 2022 by Prof Hywel Morgan and Dr Daniel Spencer. The firm focuses on healthcare/diagnostics. Primary customers are clinical laboratories and hospitals, particularly in critical care settings.
iFast Diagnostics has raised $8.8M across 2 funding rounds.
iFast Diagnostics has raised $8.8M in total across 2 funding rounds.
iFast Diagnostics has raised $8.8M in total across 2 funding rounds.
iFast Diagnostics's investors include KHP Ventures.
iFast Diagnostics has raised $8.8M across 2 funding rounds. Most recently, it raised $6.4M Seed in November 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 5, 2024 | $6.4M Seed | KHP Ventures | — | Announced |
| Mar 13, 2023 | $2.4M Venture Round | — | — | Announced |